Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.136.60 CHF
Change Today -1.70 / -1.23%
Volume 60.1K
ATLN On Other Exchanges
Symbol
Exchange
OTC US
Xetra
SIX Swiss Ex
OTC US
As of 4:07 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ATLN) Snapshot

Open
SFr.136.00
Previous Close
SFr.138.30
Day High
SFr.137.40
Day Low
SFr.136.00
52 Week High
06/11/15 - SFr.145.50
52 Week Low
01/22/15 - SFr.90.42
Market Cap
15.6B
Average Volume 10 Days
404.8K
EPS TTM
SFr.5.63
Shares Outstanding
114.1M
EX-Date
05/12/15
P/E TM
24.3x
Dividend
SFr.1.30
Dividend Yield
0.94%
Current Stock Chart for ACTELION LTD-REG (ATLN)

Related News

No related news articles were found.

actelion ltd-reg (ATLN) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ATLN) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Founded in 1997

actelion ltd-reg (ATLN) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: SFr.2.7M
Compensation as of Fiscal Year 2014.

actelion ltd-reg (ATLN) Key Developments

Actelion Ltd. Creates Vaxxilon Together with the Max Planck Society

Actelion Ltd. announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines. The new company, Vaxxilon, aims to discover, develop, and commercialize synthetic carbohydrate vaccines. Vaxxilon has licensed exclusive rights to multiple preclinical vaccine candidates and additional technologies from Max-Planck Innovation GmbH, the technology transfer office of the Max Planck Society. The first preclinical candidates were discovered and synthesized by Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, near Berlin. An additional key component of the technology was jointly developed by Prof. Seeberger and Prof. Gennaro de Libero of the University Hospital of Basel. Vaxxilon plans to advance its first vaccine candidate into man within 3 years. Vaxxilon will be headquartered in Reinach, Switzerland, and a research facility will be established in Berlin.

Actelion Creates Vaxxilon Together with the Max Planck Society

Actelion Ltd announced the creation of a start-up, together with the Max Planck Society, in the field  of synthetic carbohydrate vaccines. The  new  company,  Vaxxilon,  aims  to  discover,  develop,  and  commercialize synthetic  carbohydrate  vaccines.  Vaxxilon  has  licensed  exclusive rights to  multiple  preclinical vaccine  candidates and  additional technologies from Max- Planck  Innovation  GmbH,  the  technology  transfer  office  of  the Max Planck  Society. The company is  the  principal  investor  and  majority shareholder, having made a  funding  commitment of  up to  EUR 30 million,  to be  released in  tranches over a  period of three to four years.

Shire Mulls Actelion

Shire plc (LSE:SHP) is mulling Actelion Ltd. (SWX:ATLN) for about £12 billion, according to reports.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATLN:VX SFr.136.60 CHF -1.70

ATLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $82.02 USD +1.13
H Lundbeck A/S kr135.10 DKK -1.20
Hikma Pharmaceuticals PLC 1,941 GBp -14.00
Hospira Inc $88.95 USD +0.06
UCB SA €64.98 EUR -0.60
View Industry Companies
 

Industry Analysis

ATLN

Industry Average

Valuation ATLN Industry Range
Price/Earnings 26.5x
Price/Sales 7.9x
Price/Book 8.2x
Price/Cash Flow 23.7x
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit www.actelion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.